Literature DB >> 9708947

Cytokine production profiles in the peritoneal fluids of patients with malignant or benign gynecologic tumors.

R Punnonen1, K Teisala, T Kuoppala, B Bennett, J Punnonen.   

Abstract

BACKGROUND: Cytokines play a key role in the regulation of cells of the immune system and also have been implicated in the pathogenesis of malignant diseases. Some cytokines have been shown to have potential in the diagnosis of cancer.
METHODS: A total of 111 patients with ovarian, cervical, or endometrial carcinomas or benign ovarian or uterine tumors were enrolled on the study, and the levels of interleukin (IL)-2, IL-4, IL-6, IL-10, interferon (IFN)-gamma, granulocyte-colony stimulating factor (G-CSF), granulocyte-macrophage-colony stimulating factor (GM-CSF), macrophage-colony stimulating factor (M-CSF), and tumor necrosis factor (TNF)-alpha were measured by cytokine specific, enzyme-linked immunoadsorbent assays. In addition, ratios of IL-2, IL-4, and IFN-gamma production were studied to characterize the type of T-cell response that occurred in the peritoneal cavities of the patients.
RESULTS: High levels of M-CSF (mean for all patients, 26,050 pg/mL) and G-CSF (mean for all patients, 20,267 pg/mL) were observed in virtually all patients, but no significant differences between the study groups were observed. Similarly, no differences in the levels of IL-2, IL-4, IL-10, IFN-gamma, GM-CSF, or TNF-alpha were found. However, IL-6 levels were significantly higher in patients with ovarian carcinoma (mean +/- standard error of the mean [SEM]: 5572 +/- 1266) or benign tumors (mean +/- SEM: 4474 +/- 2008) than in those with cervical (mean +/- SEM: 1222 +/- 546) or endometrial carcinoma (mean +/- SEM: 1977 +/- 616). A predominantly Th1 type cytokine profile, irrespective of the diagnosis, was observed in patients with gynecologic tumors.
CONCLUSIONS: With the exception of IL-6, the cytokine synthesis profiles in the peritoneal fluids of patients with benign and malignant gynecologic tumors were found to be similar. These results suggest that cytokine production in these patients is a result of nonspecific inflammation rather than a specific response against the tumor cells, and that skewing of cytokine synthesis toward either the Th1 or the Th2 phenotype is not the underlying mechanism resulting in the malignant process in women with gynecologic tumors.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9708947     DOI: 10.1002/(sici)1097-0142(19980815)83:4<788::aid-cncr24>3.0.co;2-n

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  11 in total

Review 1.  Th1/Th2 balance in cancer, transplantation and pregnancy.

Authors:  M R Shurin; L Lu; P Kalinski; A M Stewart-Akers; M T Lotze
Journal:  Springer Semin Immunopathol       Date:  1999

2.  Incidence and predictors of venous thromboembolism after debulking surgery for epithelial ovarian cancer.

Authors:  Bahareh Mokri; Andrea Mariani; John A Heit; Amy L Weaver; Michaela E McGree; Janice R Martin; Maureen A Lemens; William A Cliby; Jamie N Bakkum-Gamez
Journal:  Int J Gynecol Cancer       Date:  2013-11       Impact factor: 3.437

3.  Expression of interleukin-1 (IL-1) ligands system in the most common endometriosis-associated ovarian cancer subtypes.

Authors:  Mamadou Keita; Paul Bessette; Manuella Pelmus; Youssef Ainmelk; Aziz Aris
Journal:  J Ovarian Res       Date:  2010-01-28       Impact factor: 4.234

Review 4.  The tumor microenvironment and its contribution to tumor evolution toward metastasis.

Authors:  Girieca Lorusso; Curzio Rüegg
Journal:  Histochem Cell Biol       Date:  2008-11-06       Impact factor: 4.304

Review 5.  Clinical Use of Interferon-gamma.

Authors:  Catriona H T Miller; Stephen G Maher; Howard A Young
Journal:  Ann N Y Acad Sci       Date:  2009-12       Impact factor: 5.691

6.  Profiling of cytokines in human epithelial ovarian cancer ascites.

Authors:  Isabelle Matte; Denis Lane; Claude Laplante; Claudine Rancourt; Alain Piché
Journal:  Am J Cancer Res       Date:  2012-08-20       Impact factor: 6.166

7.  Obesity, inflammatory markers, and endometrial cancer risk: a prospective case-control study.

Authors:  Laure Dossus; Sabina Rinaldi; Susen Becker; Annekatrin Lukanova; Anne Tjonneland; Anja Olsen; Jakob Stegger; Kim Overvad; Nathalie Chabbert-Buffet; Aida Jimenez-Corona; Francoise Clavel-Chapelon; Sabine Rohrmann; Birgit Teucher; Heiner Boeing; Madlen Schütze; Antonia Trichopoulou; Vassiliki Benetou; Pagona Lagiou; Domenico Palli; Franco Berrino; Salvatore Panico; Rosario Tumino; Carlotta Sacerdote; Maria-Luisa Redondo; Noémie Travier; Maria-Jose Sanchez; Jone M Altzibar; Maria-Dolores Chirlaque; Eva Ardanaz; H Bas Bueno-de-Mesquita; Fränzel J B van Duijnhoven; N Charlotte Onland-Moret; Petra H M Peeters; Goran Hallmans; Eva Lundin; Kay-Tee Khaw; Nicholas Wareham; Naomi Allen; Tim J Key; Nadia Slimani; Pierre Hainaut; Dora Romaguera; Teresa Norat; Elio Riboli; Rudolf Kaaks
Journal:  Endocr Relat Cancer       Date:  2010-10-29       Impact factor: 5.678

8.  Prognostic significance of IL-6 and IL-8 ascites levels in ovarian cancer patients.

Authors:  Denis Lane; Isabelle Matte; Claudine Rancourt; Alain Piché
Journal:  BMC Cancer       Date:  2011-05-30       Impact factor: 4.430

9.  The role of chronic inflammation in obesity-associated cancers.

Authors:  Maria E Ramos-Nino
Journal:  ISRN Oncol       Date:  2013-05-30

10.  Granulocyte colony-stimulating factor receptor signalling via Janus kinase 2/signal transducer and activator of transcription 3 in ovarian cancer.

Authors:  J Kumar; F W Fraser; C Riley; N Ahmed; D R McCulloch; A C Ward
Journal:  Br J Cancer       Date:  2013-11-12       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.